Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2

Similar documents
America, Hershey, PA Australia, Melbourne, VIC Europe, Munich

Sample validation data

Human cell line list Production of Exosome Standards - Cell Lysates

Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center

HansaBioMed Catalog 2014 for Exosome Research. X. Human Cell Lines...

Supplementary Materials for

SHN-1 Human Digestive Panel Test results

Evaluation of immunomodulatory agents in syngeneic models and immune cell phenotyping of humanized mouse models carrying patient-derived tumors

Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center

Charles River Immunodeficient Models Xenograft Data Catalog

Figure S1 Time-dependent down-modulation of HER3 by EZN No Treatment. EZN-3920, 2 μm. Time, h

Cancer model Liver metastasis I

Antitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models

OBTAIN MORE INFORMATION FROM YOUR TARGET. in vivo Imaging Agents

Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin

Outcomes Report: Accountability Measures and Quality Improvements

Icd 10 code lung ca with mets to bone

Chapter 3. Neoplasms. Copyright 2015 Cengage Learning.

Cancer A Superficial Introduction

MOLECULAR PHARMACOLOGY SUPPLEMENT

THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA

Colorectal Cancer Screening

Establishment of Human Cancer Cell Clones with Different Characteristics: A Model for Screening Chemopreventive Agents

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

List of Available TMAs in the PRN

Macmillan Publications

The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light.

Supplemental Methods LC-MS Assay for NAD Concentration

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill

Cancer Awareness Talk ICPAK 2014

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.

Supplementary Data Supplementary Table S1. IC 50 values of ipatasertib on cell viability in cell lines with

LavaCell. Fluorescent Cell Stain. (version A) Catalog No

Neoplasms/Lymphoma/Leukemia

Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence

micrornas!as! Biomarkers! Landscape!

El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD

Supplementary Materials. for Garmy-Susini, et al, Integrin 4 1 signaling is required for lymphangiogenesis and tumor metastasis

Oncology 101. Cancer Basics

Cancer in the organ donor

Respiratory Interactive Session. Elaine Borg

Tumours in the donor: what is the risk?

CODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser

Supplementary Information

Molecular Imaging of CXCR4 Receptors

Radiology Pathology Conference

Supplementary Figure 1

Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures

Cancer Metronomic Therapy Milan, February 26, 2016

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Icd 10 code for esophageal cancer stage 4

Cancer Fundamentals. Julie Randolph-Habecker, Ph.D. Director, Experimental Histopathology Shared Resource

TUMOR M ARKERS MARKERS

Targeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018

Targeting Inflammation in Breast Cancer Pathogenesis

Recurrent lung cancer icd 10

Epidemiology in Texas 2006 Annual Report. Cancer

National Cancer Drugs Fund List - Approved

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response

M e t a s t a t c a r c i n o m i c d

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

For personal use only

Citi Global Healthcare Conference

CANCER Uncontrolled Cell Division

ASCO 2014 Highlights*

Outcomes Report: Accountability Measures and Quality Improvements

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

Genetic Alteration Panels

Lecture 1: Carcinogenesis

Neoplasia 2018 lecture 11. Dr H Awad FRCPath

TITLE: Crosstalk Between Cancer Cells and Bones Via the Hedgehog Pathway Determines Bone Metastasis of Breast Cancer

Icd 10 code for lung cancer with mets to bone

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

Broad Spectrum, Targeted Approaches To Cancer Treatment

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

Metastatic esophageal cancer icd 10 code

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

The Role of CCR9 and Melanoma Metastasis to Small Intestine. Farin Amersi, MD Samuel Oschin Comprehensive Cancer Center Cedar Sinai Medical Center

PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS

The mir-199a/brm/egr1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines

CANCER THERAPEUTICS: A NOVEL APPROACH

Prostate cancer with mets to bone icd 10. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

4100: Cellular Therapy Essential Data Follow-Up Form

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

ACR TXIT TM EXAM OUTLINE

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

SUPPLEMENTARY INFORMATION

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Supplementary Material

Cancer Cases Treated and Results

Cancer of Unknown Primary (CUP) Protocol

A gene expression bar code for microarray data

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

Transcription:

America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Tissue Bladder Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc- Mouse urinary bladder carcinoma C57BL/6 KU-7-luc- GFP Brain Mouse urinary bladder carcinoma dual labeled:ex vivo cell isolation using U87MG glioblastoma; astrocytoma also available for U87MG-luc 6 U-87 MGluc glioblastoma; astrocytoma GL61-luc Murine glioblastoma multiforme extremely bright like 4T1-luc imaging from day 0 1 Breast 4 T1 Mouse breast carcinoma Balb/C Mice

Breast 4 T1-luc Mouse breast carcinoma 4t1-luc- tdtomato single cell detection in vivo Mouse breast carcinoma invasion with IHC. Ex vivo cell isolation using BT-474 breast carcinoma Oestrogen dependent, hormone pellets, HER pos -4 CCL-51 Mouse breast carcinoma lung mets 4 EMT6 Mouse breast carcinoma lung mets HCC1954 breast carcinoma slow growing, SCID CB17 Mice, HER pos 6 MCF-7 breast carcinoma Estrogen dependent, hormone pellets 4 MCF-7-luc- F5 breast adenocarcinoma Estrogen dependent, hormone pellets Lung/thoracic metastasis in nude beige (Harlan) MDA-MB-31 breast adenocarcinoma, Pleural also available: MDA-MB31-luc (vp cell line) -3

Breast MDA- MB-31-luc- D3-H1 breast adenocarcinoma, Pleural -3 MDA- MB-31-luc- D3HLN breast adenocarcinoma, Pleural, A spontaneous lymph node metastasis from a D3H1 mammary fat pad tumor more prone to methastise -3 MDA- MB-31-luctdTomato breast adenocarcinoma, Pleural invasion with IHC. Ex vivo cell isolation using -3 MDA- MB-31-luc- GFP breast adenocarcinoma, Pleural invasion with IHC -3 MDA-MB-468 breast adenocarcinoma slow growing 60 days lead time 4 Colon Colo-05 carcinoma,colorectal induction of cachexia 3-4 Colo05-luc carcinoma,colorectal. 3-4

Colon CT-6 Mouse carcinoma, colorectal HCT 116 carcinoma, colorectal also available for HCT 116-luc -4 HCT 116 luc carcinoma, colorectal. -4 HT-9 adenocarcinoma, colorectal HT-9-luc-D6 adenocarcinoma; colorectal. SCID-bg: subcutaneous metastasis to lymph node and lung. Long model up to 7 weeks LoVo-6-luc-1 adenocarcinoma; colorectal. secum wall in SCID-bg (CR) MC-38 Mouse adenocarinoma SW60 carcinoma, colorectal resistant 4 Leukemia Daudi B lymphoblast, Burkitt s lymphoma (NHL) iv injection in SCID mice 4 EL4-luc Murine Lymphoma. K-56-luc chronic myelogenous leukemia (CML).

Leukemia LP-1 Plasmacytoma, multiple myeloma (MM) NCI-H99 Plasmacytoma, multiple myeloma (MM) bone lytic when injected in bone marrow of tibia 4 bone lytic when injected in bone marrow of tibia 4 MOLT-4-luc acute lymphoblastic leukemia Perkin- Elmer, i.p and s.c. inoculation 1- MV(4)11 acute biphenotypic B monpcytic leukemia (AML) RPMI 86 Plasmacytoma, multiple myeloma (MM) i.v. injection in NOD SCID mice 4 bone lytic when injected in bone marrow of tibia 4 Ramos Burkitt s Lymphoma iv injection in SCID- C.B-17, survival model Raji B lymphoblast, Burkitt s lymphoma (NHL) Liver iv injection in SCID mice, also available for Rajiluc clone 4 Hep 3B.1-7 hepatocellular carinoma subcutaneous and orthotopic, >90% take rate 3 HepG-luc hepatocellular carinoma HUH-7 carcinoma very variable and fast growing 3 SK-HEP-1 adenocarcinoma 4

Lung Carcinoma A549-luc-C8 NSCLS carcinoma, lung. SCID-bg (CR): subcutaneous, intravenous lung colonization LL/ luc Mouse Lewis Lung (C57BL6) -3 LL/-luc-M38 Mouse Lung Cancer Perkin i.v. multiple metastasis in several mouse strains, short model 5 days 1.5 NCI-H09 SCLC, Small Cell Carcinoma NCI-H460 NSCLC, pleural effusion high variability 3 also available for NCI-H460-luc -4 Melanoma Skin B16-F0 Mouse melanoa C57 Black 6 mouse B16-F10 Mouse melanoma C57 Black 6 mouse B16-F10-luc-G5 Mouse melanoma Perkin C57BL/6 Albino (Jackson Lab) iv. multiple meths. short model 13 days 1 B16-F10-luc Mouse melanoma 40 fold brighter than luc version 1 C8161 malignant melanoma metastatic clone 3

Melanoma Skin CHL-1 melanoma fast growing G361 malignant melanoma lung and liver metastasis, induction of cachexia 4 Pancreas L3.6pL carcinoma pancectomy in preparation -4 Pan0 Mouse carcinoma C57B16 5 MIA PaCa- carcinoma in Athymic Foxn1 nude -4 PANC-1 epithelioid carcinoma SCID mice 3-6 BxPC3-luc pancreas adenocarcinoma Perkin Prostate DU 145 prostate carcinoma slow growth rate 4 LNCaP-luc-M6 prostate carcinoma Perkin hormone sensitive SCID-bg mice, pulmonary metastases LNCaP-luc-M6 prostate carcinoma Perkin 5 fold brighter than luc version -3-3

Prostate PC3 prostate adenocarcinoma also as PC3 luc (vp cell line) -3 PC-3M-luc-C6 PC-3M-luc PC-3-luc prostate adenocarcinoma Perkin also as intracardiac tumor models -3 PC-3-luc-GFP prostate adenocarcinoma Thyroid SW579 squamous cell carcinoma Gastrics Perkin invasion with IHC, Ex vivo cell isolation using -3 NCI-N87-luc- GFP stomach; derived from metastatic site liver invasion with IHC, Ex vivo cell isolation using

Tumor vascularisation hvegf-luc/ PC3M prostate cancer Oncology/Angiogenesis reporter cell line -3 other HT1080-luc Fibrosarcoma